[Osteopenia. A problem of long-term dialysis].
Hemodialysis induced osteopenia represents one of the serious late complications of long-term treatment with hemodialysis. The incidence of osteopenia in our hemodialysis-patients ranges between 5 and 10 percent (Atkinson et al. 1973; Delling et al. 1976; Heidler et al. 1976; Parfitt 1976; Fuchs et al. 1977a; Henning et al. 1977; Schulz 1978, 1979; Madsen 1979; Schulz et al. 1980, 1981). Well timed variation of the conventional electrolytecomposition of dialysate can prevent osteopenia in many cases successfully. Precise histological classification of bone (histomorphometrical evaluation of bone-biopsy) and determination of parathormon- and fluor-level are the obligatoric precondition of adequate osteopenia-treatment. Therapy of osteopenia comprises--beside decrease of dialysate calcium and -magnesium--stepwise increase of NaF--and 1,25(OH)2D3-application. Surveillance during therapy should include monitoring of calcium, phosphate and fluor-metabolism, microradioscopy of hand skeleton, rebiopsy of bone (iliac crest) and determination of iPTH.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001847:Bone Diseases / Q000188:drug therapy / Q000209:etiology*; D002117:Calcitriol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects*; D012969:Sodium Fluoride / Q000627:therapeutic use
D012969:Sodium Fluoride; D002117:Calcitriol
Osteopenie. Ein Problem der Langzeit-Dialyse.